INTRODUCTION
Anticoagulant medications help prevent clots thereby reducing the chance of developing serious conditions such as stroke, myocardial infarction, deep vein thrombosis (DVT) and pulmonary embolism. Warfarin, a vitamin K antagonist (VKA) anticoagulant is the most commonly used oral anticoagulant (OAC). Newer non-vitamin K oral antagonists (NOACS) currently available in the market include apixaban, dabigatran and rivaroxaban.
Oral anticoagulants are associated with adverse events such as abnormal coagulation and bleeding. Patients treated with warfarin require close monitoring to avoid adverse events related to bleeding. NOACs are reported to have better safety and efficacy profiles which should translates to less monitoring and more convenience for patients and physicians. The lack of available antidotes for NOACs has hindered their adoption for use. Recently an antidote has been approved for reversing the effects of dabigatran and antidotes for other NOACs are in clinical development. Usage of NOACs is expected to increase substantially with the approval of these reversal agents/antidotes. This study examined all-cause and bleeding-event related resource utilization (office visits, emergency department [ED] visits, hospital admissions) among patients on OAC therapy.
OBJECTIVE
A retrospective analysis was conducted using Mississippi Medicaid pharmacy and medical claims data from January 2014 to November 2015. Claims for fee-for-service and encounter records for both managed care plans were included in the analyses. Beneficiaries who had at least one prescription for an OAC during the observation period were included in the study. Resource utilization was classified as OAC-related if the medical claim included a diagnosis code for a bleeding event. Diagnosis codes for OAC related bleeding events were identified by ICD-9 and ICD-10 codes obtained by literature review. With the exception of warfarin, the analyses were performed for each drug strength, since specific strengths of the drugs are used for different indications.
METHODS

CONCLUSION
Rates for bleeding related ED visits were lower for NOACs than for warfarin. Higher doses of rivaroxaban were related to increased risk of bleeding related ED visits, but other conclusive comparisons between NOACs could not be made due to the limited number of patients on most of the medications.
